Methadone News and Research

RSS

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol) in the US, in line with the Daiichi Sankyo strategy to expand its US portfolio through strategic alliances, in addition to internal R&D and acquisitions.

19 Mar 2015

Opioid withdrawal in Ontario newborns increases 15-fold

The number of newborns suffering from opioid withdrawal increased 15-fold in Ontario over 20 years, according to research published today in CMAJ Open.

12 Feb 2015

Use of methadone drug to treat pain increases mortality risk

Outside the hospital, use of methadone to treat pain carries a 46 percent increased risk of death when compared to the equally effective but more costly alternative, morphine SR (sustained release).

21 Jan 2015

New experimental study shows immunotherapy can reduce acute effects of heroin

Immunotherapy could have a place in the treatment of substance abuse in the future. A specific antibody can reduce the acute effects of heroin, according to a new experimental study at the Norwegian Institute of Public Health.

21 Jan 2015

European countries implement ATOME project to study improved access to essential painkillers

Governments in 12 European countries are to implement the recommendations of research into why more patients are not receiving essential painkillers.

15 Jan 2015

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients.

4 Dec 2014

Montefiore Medical Center receives $3.5M grant to advance treatment for hepatitis C

Montefiore Medical Center received a $3.5 million grant as part of the $10 million Health Care Innovation Award from the Center for Medicare & Medicaid Services to identify, diagnose and treat people with hepatitis C (HCV).

13 Nov 2014

Prescription opioids involved in 67.8% of nationwide ED visits in 2010, find researchers

Researchers from Rhode Island and The Miriam hospitals and the Stanford University School of Medicine have found that prescription opioids, including methadone, were involved in 67.8 percent of (or over 135,971 visits to) nationwide emergency department (ED) visits in 2010, with the highest proportion of opioid overdoses occurring in the South.

12 Nov 2014

RAND study: Specific state guidance can influence patient access to effective heroin treatment

State policies can influence the number of physicians licensed to prescribe buprenorphine, a drug that can treat addiction to heroin and other opioids in outpatient settings, according to a new RAND Corporation study.

8 Oct 2014

AAN releases new position statement on opioids for chronic non-cancer pain

According to a new position statement from the American Academy of Neurology, the risk of death, overdose, addiction or serious side effects with prescription opioids outweigh the benefits in chronic, non-cancer conditions such as headache, fibromyalgia and chronic low back pain.

30 Sep 2014

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.

11 Sep 2014

Low dose of opioids including methadone effective for treatment of testosterone suppression

Treatment for opioid addiction tampers with the testosterone levels of male but not female opioid users, McMaster University research has shown.

26 Aug 2014

Researchers focus on how exposure to opioids may alter expression of OPRM1 gene

Some infants born with neonatal abstinence syndrome (NAS) secondary to in-utero opioid exposure have a more difficult time going through withdrawal than others, but the underlying reasons are not well understood.

20 Aug 2014

New therapeutic drug may prevent respiratory depression in patients taking opioid medication

People taking prescription opioids to treat moderate to severe pain may be able to breathe a little easier, literally.

20 Aug 2014

Rockefeller scientists identify protein that makes breast cancer cells more likely to metastasize

Using an innovative tool that captures heretofore hidden ways that cells are regulated, scientists at Rockefeller University have identified a protein that makes breast cancer cells more likely to metastasize.

10 Jul 2014

Prescription drug deaths drop in Fla. after crackdown on doctors

Deaths involving narcotic painkillers dropped 26 percent over two years in Florida after stricter doctor scrutiny, according to a report from the federal Centers for Disease Control and Prevention.

2 Jul 2014

State highlights: Ohio managed care plans launch; Bluecross Blueshield plan faces Ore. lawsuit; N.Y. policy on unvaccinated children upheld

A selection of health policy stories from Ohio, Oregon, New York, Colorado, Iowa, New Jersey, North Carolina, Georgia, California and Minnesota.

24 Jun 2014

Researchers find sharp increase in deaths from commonly prescribed painkillers in US, Canada

The number of deaths involving commonly prescribed painkillers is higher than the number of deaths by overdose from heroin and cocaine combined, according to researchers at McGill University.

18 Jun 2014

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT®) and ViiV's Integrase Inhibitor dolutegravir(marketed as TIVICAY®) as the sole active ingredients for the maintenance treatment of people living with Human Immunodeficiency Virus (HIV).

12 Jun 2014

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences International, Inc. received approval of the New Drug Application (NDA) for BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA).

9 Jun 2014